Cytosorbents (CTSO) Share-based Compensation Growth (1y) (2011 - 2026)
Cytosorbents (CTSO) Share-based Compensation Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.44 Bn | 193.84 Bn | 7.27 Bn | 18.31% |
| 2 | Stryker | 127.32 Bn | 123.85 Bn | 4.50 Bn | -78.13% |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | 6.74% |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | 16.00% |
| 5 | Edwards Lifesciences | 51.90 Bn | 47.65 Bn | 1.35 Bn | 12.53% |
| 6 | Dexcom | 34.30 Bn | 32.36 Bn | 830.00 Mn | -13.91% |
| 7 | GE HealthCare Technologies | 33.74 Bn | 31.63 Bn | 2.18 Bn | 60.71% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 5.29% |
| 9 | Steris | 23.05 Bn | 22.56 Bn | 684.20 Mn | 7.56% |
| 10 | Cytosorbents | 21.98 Mn | 17.56 Mn | 7.05 Mn | -35.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -35.55% |
| Mar 31, 2026 | -33.50% |
| Dec 31, 2025 | -3.70% |
| Sep 30, 2025 | 135.69% |
| Jun 30, 2025 | -42.26% |
| Mar 31, 2025 | 40,315.02% |
| Dec 31, 2024 | -13.88% |
| Sep 30, 2024 | -17.96% |
| Jun 30, 2024 | 73.51% |
| Mar 31, 2024 | -99.81% |
| Dec 31, 2023 | 22.79% |
| Sep 30, 2023 | 8.06% |
| Jun 30, 2023 | -25.10% |
| Mar 31, 2023 | 36.85% |
| Dec 31, 2022 | 137.90% |
| Sep 30, 2022 | 0.60% |
| Jun 30, 2022 | -51.16% |
| Mar 31, 2022 | -49.49% |
| Dec 31, 2021 | -1,253.74% |
| Sep 30, 2021 | -8.18% |